Amarin Announces U.S. Patent 8,318,715 Issuance for Vascepa(R) Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces U.S. Patent 8,318,715 Issuance for Vascepa(R)
AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type 2) to be Presented at the American Diabetes Association's 72nd Scientific Sessions Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type 2) to be Presented at the American Diabetes Association's 72nd Scientific Sessions
Amarin Announces Notice of Allowance for Additional U.S. Patent Covering AMR101 Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Announces Notice of Allowance for Additional U.S. Patent Covering AMR101
Amarin Announces Publication of ANCHOR Phase 3 Clinical Trial Results in The American Journal of Cardiology Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Announces Publication of ANCHOR Phase 3 Clinical Trial Results in The American Journal of Cardiology
Amarin Receives Notice of Intention to Grant on European Patent Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Receives Notice of Intention to Grant on European Patent
Amarin Announces FDA Approval of Vascepa(TM) (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Announces FDA Approval of Vascepa(TM) (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia
Amarin to Report Second Quarter 2012 Financial Results and Host Conference Call on August 8, 2012 Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin to Report Second Quarter 2012 Financial Results and Host Conference Call on August 8, 2012
Amarin Reports Second Quarter 2012 Financial Results and Provides Update on Operations Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Reports Second Quarter 2012 Financial Results and Provides Update on Operations
Amarin Announces Additional Publication of MARINE Phase 3 Clinical Trial Results in the Journal of Clinical Lipidology Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Announces Additional Publication of MARINE Phase 3 Clinical Trial Results in the Journal of Clinical Lipidology
Amarin Announces Notification of Patent Allowance for U.S. Application 13/282,145 Related to Vascepa(TM) and FDA Approved MARINE Indication Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Announces Notification of Patent Allowance for U.S. Application 13/282,145 Related to Vascepa(TM) and FDA Approved MARINE Indication
